Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03599193 · ClinicalTrials.gov registry record · Phase 2
A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris
A Phase 2 study, sponsored by Dr. Reddy's Laboratories Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT03599193 is a Phase 2 study that has completed, run by Dr. Reddy's Laboratories Limited. The registered enrollment target is 58 participants.
The verdict
NCT03599193, a Phase 2 study, has completed, sponsored by Dr. Reddy's Laboratories Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This was a multicenter, randomized, multiple-dose, laboratory-blinded, open-label, 2-arm, parallel-arm study in subjects with moderate acne vulgaris.
Interventions
- DRUG Tazarotene Cream, 0.1%
- DRUG Tazarotene Lotion, 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2017-10-04 |
| Est. Completion | 2018-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03599193
The ClinicalTrials.gov registry entry for NCT03599193 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dr. Reddy's Laboratories Limited, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tazarotene Cream, 0.1% is the first listed.
NCT03599193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03599193 about?
NCT03599193 is a clinical study titled "A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris". This was a multicenter, randomized, multiple-dose, laboratory-blinded, open-label, 2-arm, parallel-arm study in subjects with moderate acne vulgaris.
What is the current status of trial NCT03599193?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2017-10-04. Estimated completion is 2018-04-30.
What interventions are being tested in trial NCT03599193?
The interventions under investigation include: Tazarotene Cream, 0.1% (DRUG), Tazarotene Lotion, 0.1% (DRUG).
Who is sponsoring clinical trial NCT03599193?
This trial is sponsored by Dr. Reddy's Laboratories Limited, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.